keyword
MENU ▼
Read by QxMD icon Read
search

atazanavir

keyword
https://www.readbyqxmd.com/read/28333353/evolution-of-blood-associated-hiv-1-dna-levels-after-48-weeks-of-switching-to-atazanavir-ritonavir-lamivudine-dual-therapy-versus-continuing-triple-therapy-in-the-randomized-atlas-m-trial
#1
Francesca Lombardi, Simone Belmonti, Eugenia Quiros-Roldan, Alessandra Latini, Antonella Castagna, Gabriella D'Ettorre, Roberta Gagliardini, Massimiliano Fabbiani, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto
Objectives: The AtLaS-M randomized trial showed that in patients with HIV-1 RNA <50 copies/mL on atazanavir/ritonavir + two NRTIs, switching to a dual therapy with atazanavir/ritonavir+lamivudine had superior efficacy as compared with continuing the previous triple therapy. This substudy was designed to evaluate at 48 weeks the impact of the dual therapy versus the three-drug atazanavir/ritonavir-based therapy on the HIV-1 cellular reservoir as reflected by the quantification of blood-associated HIV-1 DNA levels...
March 10, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28333285/therapeutic-drug-monitoring-of-boosted-pis-in-hiv-positive-patients-undetectable-plasma-concentrations-and-risk-of-virological-failure
#2
A Calcagno, N Pagani, A Ariaudo, G Arduino, C Carcieri, A D'Avolio, L Marinaro, M C Tettoni, L Trentini, G Di Perri, S Bonora
Background: Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure. Methods: A TDM registry study and a retrospective follow-up study were conducted. Plasma concentrations were measured through validated methods...
March 10, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28322573/blood-lead-levels-and-neurodevelopmental-function-in-perinatally-hiv-exposed-uninfected-children-in-a-us-based-longitudinal-cohort-study
#3
Katherine Tassiopoulos, Yanling Huo, Joseph Braun, Paige L Williams, Renee Smith, Ann Aschengrau, Sharon Nichols, Rohan Hazra, William A Meyer, Katherine Knapp, Nagamah S Deygoo, George R Seage Iii
BACKGROUND: While children's exposure to environmental lead in the U.S. has decreased, areas of elevated levels remain. Because lead exposure is a risk factor for developmental delays, it should be considered when studying neurodevelopmental effects of in-utero antiretroviral medication (ARV) exposure in the growing population of perinatally HIV-exposed, uninfected children (PHEU). We compared blood lead levels (BPb) in PHEU children enrolled in the Surveillance Monitoring of ART Toxicities (SMARTT) Study to U...
March 21, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/28298195/role-of-systemic-inflammation-scores-for-prediction-of-clinical-outcomes-in-patients-treated-with-atazanavir-not-boosted-by-ritonavir-in-the-italian-master-cohort
#4
Maria Concetta Postorino, Mattia Prosperi, Emanuele Focà, Eugenia Quiros-Roldan, Elisa Di Filippo, Franco Maggiolo, Alberto Borghetti, Nicoletta Ladisa, Massimo Di Pietro, Andrea Gori, Laura Sighinolfi, Angelo Pan, Nicola Mazzini, Carlo Torti
BACKGROUND: Atazanavir (ATV) not boosted by ritonavir (uATV) has been frequently used in the past for switching combination antiretroviral therapy (cART). However, the clinical outcomes and predictors of such strategy are unknown. METHODS: An observational study was carried out on the Italian MASTER, selecting HIV infected patients on cART switching to an uATV-containing regimen. Baseline was set as the last visit before uATV initiation. In the primary analysis, a composite clinical end-point was defined as the first occurring of any condition among: liver, cardiovascular, kidney, diabetes, non AIDS related cancer or death events...
March 15, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28287204/-biliary-and-kidney-lithiasis-during-treatment-with-daclatasvir-sofosbuvir-ribavirin-and-atazanavir-ritonavir-abacavir-lamivudine-in-an-hiv-hcv-genotype-4-infected-patient-a-case-report
#5
Andrea Vavassori, Paola Lanza, Ilaria Izzo, Salvatore Casari, Silvia Odolini, Serena Zaltron, Elena Festa, Francesco Castelli
New Direct-acting Antiviral Agents (DAA)-based anti-HCV therapies currently provide extraordinary opportunities to cure patients. Drug-drug interactions are however a real challenge during treatment. In particular, in HIV-infected patients in cART, DAA choice is limited by such interactions, which can result both in reduced efficacy and toxicity. We report the case of a HIV-infected patient on cART with atazanavir/ritonavir/abacavir/lamivudine, who presented kidney and biliary lithiasis, the latter treated with endoscopic retrograde cholangiopancreatography and endoscopic biliary sphincterotomy, after beginning anti-HCV treatment with daclatasvir/sofosbuvir/ribavirin...
February 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28280375/budget-impact-analysis-of-the-simplification-to-atazanavir-ritonavir-lamivudine-dual-therapy-of-hiv-positive-patients-receiving-atazanavir-based-triple-therapies-in-italy-starting-from-data-of-the-atlas-m-trial
#6
Umberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, Carmela Nappi, Davide Croce
BACKGROUND: This analysis aimed at evaluating the impact of a therapeutic strategy of treatment simplification of atazanavir (ATV)+ ritonavir (r) + lamivudine (3TC) in virologically suppressed patients receiving ATV+r+2 nucleoside reverse transcriptase inhibitors (NRTIs) on the budget of the Italian National Health Service (NHS). METHODS: A budget impact model with a 5-year time horizon was developed based on the clinical data of Atlas-M trial at 48 weeks (in terms of percentage of patients experiencing virologic failure and adverse events), from the Italian NHS perspective...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28263463/drug-and-drug-abuse-associated-hyperbilirubinemia-experience-with-atazanavir
#7
Jayanta Roy-Chowdhury, Namita Roy-Chowdhury, Irving Listowsky, Allan W Wolkoff
Hyperbilirubinemia is a common finding in individuals with a history of substance abuse. Although this may indicate a serious disorder of liver function, this is not always the case. An understanding of bilirubin formation, metabolism, and transport can provide a helpful approach to dealing with these patients. This is typified by studies of patients treated with the antiretroviral drug atazanavir. Atazanavir has been associated with hyperbilirubinemia in as many as one-third of individuals for whom it has been prescribed, evoking concerns of hepatotoxicity...
March 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28263457/ombitasvir-paritaprevir-ritonavir-and-dasabuvir-drug-interactions-with-antiretroviral-agents-and-drugs-forsubstance-abuse
#8
Jennifer R King, Rajeev M Menon
AbbVie's 3 direct-acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Safe and efficacious antiviral regimens resulting in minimal to no drug-drug interactions (DDIs) with antiretrovirals are needed to ensure that patients coinfected with HCV and the human immunodeficiency virus (HIV) achieve 12-week sustained virologic response rates similar to HCV-monoinfected patients...
March 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28207816/hiv-drug-therapy-duration-a-swedish-real-world-nationwide-cohort-study-on-infcarehiv-2009-2014
#9
Amanda Häggblom, Stefan Lindbäck, Magnus Gisslén, Leo Flamholc, Bo Hejdeman, Andreas Palmborg, Amy Leval, Eva Herweijer, Sverrir Valgardsson, Veronica Svedhem
BACKGROUND: As HIV infection needs a lifelong treatment, studying drug therapy duration and factors influencing treatment durability is crucial. The Swedish database InfCareHIV includes high quality data from more than 99% of all patients diagnosed with HIV infection in Sweden and provides a unique opportunity to examine outcomes in a nationwide real world cohort. METHODS: Adult patients who started a new therapy defined as a new 3rd agent (all antiretrovirals that are not N[t]RTIs) 2009-2014 with more than 100 observations in treatment-naive or treatment-experienced patients were included...
2017: PloS One
https://www.readbyqxmd.com/read/28207500/strategic-use-of-dual-regimens-of-boosted-protease-inhibitors-plus-maraviroc-in-poorly-adherent-subjects-in-view-of-long-acting-drugs-a-retrospective-study
#10
Amedeo Ferdinando Capetti, Mariangela Micale, Laura Carenzi, Fosca Niero, Simona Landonio, Stefania Vimercati, Gianfranco Dedivitiis, Giuliano Rizzardini
In view of the forthcoming long-acting antiretrovirals, measures should be taken to prevent the selection of HIV drug resistance mutations. All subjects who had been switched to boosted protease inhibitors plus maraviroc (bPIs/MVC) with baseline HIV-1 RNA >50 copies/mL between June, 2014, and April, 2015, were retrospectively evaluated. HIV-1 RNA, CD4+ T-cells, serum glucose, creatinine, ALT, and adverse events were controlled every 3 to 4 months. We retrospectively analyzed 44 patients: 18 were taking darunavir/ritonavir (DRV/r) and 26 atazanavir/ritonavir (ATV/r) once daily, plus MVC 300 mg once daily...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28197526/indinavir-and-atazanavir-comparison-of-predicted-property-by-chemoinformatics-technique-and-implication-on-renal-problem-in-hiv-infected-patients
#11
Beuy Joob, Viroj Wiwanitkit
No abstract text is available yet for this article.
2017: J Nephropharmacol
https://www.readbyqxmd.com/read/28155724/structural-analyses-of-2015-updated-drug-resistant-mutations-in-hiv-1-protease-an-implication-of-protease-inhibitor-cross-resistance
#12
Chinh Tran-To Su, Wei-Li Ling, Wai-Heng Lua, Yu-Xuan Haw, Samuel Ken-En Gan
BACKGROUND: Strategies to control HIV for improving the quality of patient lives have been aided by the Highly Active Anti-Retroviral Therapy (HAART), which consists of a cocktail of inhibitors targeting key viral enzymes. Numerous new drugs have been developed over the past few decades but viral resistances to these drugs in the targeted viral enzymes are increasingly reported. Nonetheless the acquired mutations often reduce viral fitness and infectivity. Viral compensatory secondary-line mutations mitigate this loss of fitness, equipping the virus with a broad spectrum of resistance against these drugs...
December 22, 2016: BMC Bioinformatics
https://www.readbyqxmd.com/read/28134625/autophagy-facilitates-macrophage-depots-of-sustained-release-nanoformulated-antiretroviral-drugs
#13
Divya Prakash Gnanadhas, Prasanta K Dash, Brady Sillman, Aditya N Bade, Zhiyi Lin, Diana L Palandri, Nagsen Gautam, Yazen Alnouti, Harris A Gelbard, JoEllyn McMillan, R Lee Mosley, Benson Edagwa, Howard E Gendelman, Santhi Gorantla
Long-acting anti-HIV products can substantively change the standard of care for patients with HIV/AIDS. To this end, hydrophobic antiretroviral drugs (ARVs) were recently developed for parenteral administration at monthly or longer intervals. While shorter-acting hydrophilic drugs can be made into nanocarrier-encased prodrugs, the nanocarrier encasement must be boosted to establish long-acting ARV depots. The mixed-lineage kinase 3 (MLK-3) inhibitor URMC-099 provides this function by affecting autophagy. Here, we have shown that URMC-099 facilitates ARV sequestration and its antiretroviral responses by promoting the nuclear translocation of the transcription factor EB (TFEB)...
March 1, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28121667/improved-kidney-function-in-patients-who-switch-their-protease-inhibitor-from-atazanavir-or-lopinavir-to-darunavir
#14
Sophie Jose, Mark Nelson, Andrew Phillips, David Chadwick, Roy Trevelion, Rachael Jones, Deborah I Williams, Lisa Hamzah, Caroline A Sabin, Frank A Post
OBJECTIVE: Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV). We examined kidney function in patients who switched their protease inhibitor from ATV or LPV to DRV. DESIGN: Cohort study. METHODS: Data were from the UK CHIC study. We compared pre and post switch estimated glomerular filtration rate (eGFR) slopes (expressed in ml/min per 1...
February 20, 2017: AIDS
https://www.readbyqxmd.com/read/28109702/population-pharmacokinetics-and-dose-optimisation-of-ritonavir-boosted-atazanavir-in-thai-hiv-infected-patients
#15
Baralee Punyawudho, Narukjaporn Thammajaruk, Kiat Ruxrungtham, Anchalee Avihingsanon
There is evidence that Thai patients receiving standard doses of ritonavir (RTV)-boosted atazanavir (ATV/r) have high exposure to atazanavir (ATV) leading to a higher risk of toxicity. A lower dose of ATV/r may provide adequate exposure in this population. However, pharmacokinetic data on ATV/r in Thai patients required for dose adjustment are limited. This study aimed to develop a population pharmacokinetic model of ATV/r and to determine the influence of patient characteristics on ATV pharmacokinetics. Monte Carlo simulations were performed to estimate the proportion of patients achieving target ATV trough concentration (Ctrough) with the standard ATV/r dose of 300/100 mg and a low dose of 200/100 mg once daily (OD)...
March 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28099408/multiphenotype-association-study-of-patients-randomized-to-initiate-antiretroviral-regimens-in-aids-clinical-trials-group-protocol-a5202
#16
Anurag Verma, Yuki Bradford, Shefali S Verma, Sarah A Pendergrass, Eric S Daar, Charles Venuto, Gene D Morse, Marylyn D Ritchie, David W Haas
BACKGROUND: High-throughput approaches are increasingly being used to identify genetic associations across multiple phenotypes simultaneously. Here, we describe a pilot analysis that considered multiple on-treatment laboratory phenotypes from antiretroviral therapy-naive patients who were randomized to initiate antiretroviral regimens in a prospective clinical trial, AIDS Clinical Trials Group protocol A5202. PARTICIPANTS AND METHODS: From among 5 9545 294 polymorphisms imputed genome-wide, we analyzed 2544, including 2124 annotated in the PharmGKB, and 420 previously associated with traits in the GWAS Catalog...
March 2017: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/28094565/the-decline-in-hiv-1-drug-resistance-in-heavily-antiretroviral-experienced-patients-is-associated-with-optimized-prescriptions-in-a-treatment-roll-out-program-in-mexico
#17
Juan J Calva, Silvana Larrea, Marco A Tapia-Maltos, Mauricio Ostrosky-Frid, Carolina Lara, Pedro Aguilar-Salinas, Héctor Rivera, Juan P Ramírez
A decrease in the rate of acquired antiretroviral (ARV) drug-resistance (ADR) over time has been documented in high-income settings, but data on the determinants of this phenomenon are lacking. We tested the hypothesis that in heavily ARV-experienced patients in the Mexican ARV therapy (ART) roll-out program, the drop in ADR would be associated with changes in ARV drug usage. Genotypic resistance tests obtained from 974 HIV-infected patients with virologic failure and at least 2 previously failed ARV regimens from throughout the country were analyzed for the presence of nRTI, NNRTI and PI resistance-associated mutations (RAMs)...
January 17, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/28093483/treatment-simplification-to-atazanavir-ritonavir%C3%A2-%C3%A2-lamivudine-versus-maintenance-of-atazanavir-ritonavir%C3%A2-%C3%A2-two-nrtis-in-virologically-suppressed-hiv-1-infected-patients-48-week-results-from-a-randomized-trial-atlas-m
#18
Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quiros Roldan, Alessandra Latini, Gabriella D'Ettorre, Andrea Antinori, Antonella Castagna, Giancarlo Orofino, Daniela Francisci, Pierangelo Chinello, Giordano Madeddu, Pierfrancesco Grima, Stefano Rusconi, Massimo Di Pietro, Annalisa Mondi, Nicoletta Ciccarelli, Alberto Borghetti, Emanuele Focà, Manuela Colafigli, Andrea De Luca, Roberto Cauda
BACKGROUND: Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir  +  lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients. METHODS: We performed an open-label, multicentre, randomized, non-inferiority study, enrolling HIV-infected adults on atazanavir/ritonavir + two NRTIs, with stable HIV-RNA <50 copies/mL and CD4 + >200 cells/mm(3) Main exclusion criteria were hepatitis B virus coinfection, past virological failure on or resistance to study drugs, recent AIDS and pregnancy...
January 15, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28067119/efficacy-and-safety-of-unboosting-atazanavir-in-a-randomized-controlled-trial-among-hiv-infected-patients-receiving-tenofovir-df
#19
Marianne Harris, Bruce Ganase, Birgit Watson, Mark W Hull, Silvia A Guillemi, Wendy Zhang, Ramesh Saeedi, P Richard Harrigan
OBJECTIVES: To assess safety and efficacy of a switch to unboosted atazanavir (ATV) among HIV-infected adults receiving ATV/ritonavir (r) and tenofovir disoproxil fumarate (TDF). METHODS: HIV-infected adults with viral load (VL) <40 copies/mL at screening and <150 copies/mL consistently for ≥3 months while receiving a regimen including ATV/r and TDF were randomized to continue ATV/r 300/100 mg daily (control) or change to ATV 400 mg daily (switch), while maintaining their TDF backbone...
January 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/28065890/impact-of-obesity-on-antiretroviral-pharmacokinetics-and-immuno-virological-response-in-hiv-infected-patients-a-case-control-study
#20
Vincent Madelain, Minh P Le, Karen Champenois, Charlotte Charpentier, Roland Landman, Veronique Joly, Patrick Yeni, Diane Descamps, Yazdan Yazdanpanah, Gilles Peytavin
BACKGROUND: Obesity has high prevalence among HIV-infected patients. Increased adipose tissue mass affects the pharmacokinetics of numerous drugs, but few data are available for antiretroviral drugs. OBJECTIVES: In this study we aimed to explore the pharmacokinetics of antiretroviral drugs and the immuno-virological response in obese patients with HIV infection. PATIENTS AND METHODS: We examined data from 2009 to 2012 in our hospital's database for HIV-1-infected patients who received an antiretroviral drug (abacavir, emtricitabine, lamivudine, tenofovir, efavirenz, etravirine, nevirapine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir or raltegravir)...
January 8, 2017: Journal of Antimicrobial Chemotherapy
keyword
keyword
114247
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"